Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Runxia Gu
The liver-secreted protein FGL1 restrains a subset of innate-like B cell responses via the receptor TACI
Keywords FGL1 TACI BAFF APRIL LAG-3 BCMA B cell inhibitory autoimmunity lupus Get full text access Log in, subscribe or purchase for full access. References 1. Zhu, Y. ∙ Yao, S. ∙ Chen, L. Cell surface signaling molecules in the control of immune responses: a tide model Immunity. 2011; 34:466-478 2. Chen, L. ∙ Flies, D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 2013; 13:227-242 3.
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial | Leukemia
Correction to: Leukemia https://doi.org/10.1038/s41375-025-02674-8, published online 30 June 2025 The name of co-author Dr. Wenbing Liu was inadvertently misspelled as “Wenbin Liu”. The correct spelling should be “Wenbing Liu”. The original article has been corrected. About this article Gong, X., Liu, W., Liu, Y. et al.
Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia - Journal of Translational Medicine
Patient immunophenotype data were obtained from the Clinical Flow Cytometry Center of Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC). The expression data of AML from The Cancer Genome Atlas (TCGA) dataset as well as the expression data of Genotype-Tissue Expression Project (GTEx) normal tissues were downloaded from the UCSC Xena website (https://xena.ucsc.edu/).
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial | Leukemia
Abstract Tyrosine kinase inhibitors (TKIs) combined with chemotherapy and immunotherapy evolved as the standard treatment for newly diagnosed (ND) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nonetheless, the efficacy and safety of combining TKIs with BCL-2 inhibitors in ND Ph+ ALL have yet to be fully elucidated.
Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia
CONFLICT OF INTEREST STATEMENT Jianxiang Wang reports personal/consulting fees from AbbVie outside the submitted work. The remaining authors disclosed no conflicts of interest. Supporting Information Filename Description cncr35641-sup-0001-suppl-data.docx1.3 MB Supplementary Material REFERENCES 1, , , et al.
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients - Leukemia
Reconstructing the clonal evolution paradigm helps us understand the process of lineage switching [6]. Therefore, we depicted the clonal evolution pattern of patient 1 (P01) through single-cell targeted DNA sequencing (Supplementary Table 3). Through single-cell genomic sequencing and quality control, we obtained a total of 6566 high-quality cells with related gene mutations (FLT3, BCORL1, and STAG2) at the four time points for clone structure inference (Fig. 1B, Supplementary Table 4).
Evaluation of pretreatment telomere length as a prognostic marker in intermediate‐risk acute myeloid leukemia
ORIGINAL ARTICLE Runxia Gu, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China Search for more papers by this author Jingjing Cao, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical...
Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function | Immunotherapy
Shuning Wei‡ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China , Runxia Gu‡ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,...
The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
Hematopoietic recovery is considered to be associated with the number of multipotent hematopoietic stem cells in the bone marrow, as observed in functional assays involving stem cell transplantation. However, there is little evidence related to hematopoietic recovery in non-transplantation settings, which is accomplished by endogenous hematopoietic cells.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Runxia
Contact Runxia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack